Singapore-based biotechnology startup Mirxes is planning its initial public offering on the Hong Kong stock exchange after raising $50 million in Series D funding that valued the company at $600 million post-money.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
